Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0P9KA
|
||||
| Former ID |
DIB016578
|
||||
| Drug Name |
YM-16151-4
|
||||
| Synonyms |
YM-151; YM-16151-1; (-)-YM-16151-1
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hypertension [ICD9: 401; ICD10:I10-I16] | Phase 1 | [1] | ||
| Company |
Yamanouchi Pharmaceutical Co Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C30H37N3O9
|
||||
| Canonical SMILES |
C1(=C(NC(=C(C1c1cc([N+](=O)[O-])ccc1OCCCCNCC(COc1ccccc1<br />)O)C(=O)OC)C)C)C(=O)OC.Cl
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Beta-1 adrenergic receptor | Target Info | Modulator | [1] | |
| Calcium channel | Target Info | Modulator | [1] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Endocytosis | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Gap junction | |||||
| Salivary secretion | |||||
| Dilated cardiomyopathy | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Beta1 adrenergic receptor signaling pathway | |||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Adrenoceptors | ||||
| G alpha (s) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Endothelin Pathways | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.